Article
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Japanese journal of clinical oncology - 1 May 2016
Inoue Akira, Yoshida Kazushi, Morita Satoshi, Imamura Fumio, Seto Takashi, Okamoto Isamu, Nakagawa Kazuhiko, Yamamoto Nobuyuki, Muto Satoshi, Fukuoka Masahiro
Abstract excerpt
BACKGROUND: The Japan Guidelines of Lung Cancer Therapy recommend epidermal growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent non-small cell lung cancer patients with epidermal growth factor receptor mutation. Although survival periods in recent reports of epidermal growth factor receptor-tyrosine kinase inhibitor treatment have been getting longer, the reasons why...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.